Abstract: The prevalence of allergic conjunctivitis is increasing worldwide, which leads to a considerable effect on patient quality of life, reduces work productivity, and increases health care costs. The pharmaceutical management of allergic conjunctivitis provides only transient relief from symptoms. Allergen-specific immunotherapy (allergen-specific immunotherapy, AIT) via subcutaneous (subcutaneous allergen immunotherapy, SCIT) and sublingual (sublingual allergen immunotherapy, SLIT) routes has disease-modifying effects and can induce immune tolerance to allergens. Lots of literature suggests that, AIT can not only improve the symptoms of allergic conjunctivitis and increase threshold of reactivity to allergens, but also showed a beneficial long-term effect. However, both SCIT and SLIT can introduce local and systemic allergic reactions. Poor patient compliance and prolonged course are major shortcomings of AIT. In the future, new forms with short-term treatment period and alternative application routes can be developed to provide patients with more convenient and safer options.